CLINICAL TRIAL: PHASE II TRIAL OF IDB 1016 IN ADULT DIABETIC PATIENTS WITH NASH

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 与卵磷脂安慰剂相比，Siliphos治疗6周是否安全且耐受良好？ 在患有脂肪性肝炎的糖尿病成人患者中，通过血清氨基转移酶水平评估，Siliphos治疗导致的胰岛素抵抗和/或氧化应激改善是否会导致脂肪肝活动性改善？

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Will treatment with Siliphos for six weeks be safe and well tolerated in comparison to lecithin placebo? In diabetic adult patients with steatohepatitis, will improvement in insulin resistance and/or oxidative stress due to treatment with Siliphos result in inprovement in fatty liver disease activity as assessed by serum aminotransferese levels?